Sites of relapse and subsequent therapy in the BR.31 phase 3 study of durvalumab vs placebo in resected stage IB-IIIA NSCLC

Etude concernée: IFCT-1401
Auteurs / Authors: V. Westeel , G. Goss , G. Darling , K. Nakagawa , B. Massuti Sureda , F. Perrone , S-A. McLachlan , J.H. Kang , Y-L. Wu ,A-M.C. Dingemans, R. Dziadziuszko, M. Okada, L. Greillier, C. Audigier-Valette, F. Morin, S. Sugawara, E. Nadal, M.R. Stockler, K. Ding, C. O’Callaghan
Journal / Conference: ELCC
Année / Year: 2025
PMID: Late breaking abstract
Lien vers la publication: https://www.jto.org/article/S1556-0864(25)00330-2/fulltext